Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q2 2022 (← Previous) (Next →)

Filing Date: Aug 11, 2022

Total Value: $65.23M (100.0% shares, 0.0% debt)

Holdings (8)

CRSP CRISPR Therapeutics AG 46.4%

Value $30.3M Shares 498,558 Est. Cost $40.26 Unrealized +46.0%

— Passage Bio, Inc. 17.9%

Value $11.71M Shares 4,959,769 Est. Cost $17.48 Unrealized —

— Gritstone Oncology, Inc. 13.2%

Value $8.618M Shares 3,561,150 Est. Cost $7767.86 Unrealized —

— Adverum Biotechnologies, Inc. 9.3%

Value $6.082M Shares 5,068,233 Est. Cost $9646.10 Unrealized —

— Minerva Surgical Inc. 6.0%

Value $3.933M Shares 1,673,700 Est. Cost $5.14 Unrealized —

— Aligos Therapeutics, Inc. 4.3%

Value $2.808M Shares 2,320,381 Est. Cost $27.65 Unrealized —

— CymaBay Therapeutics, Inc. 2.5%

Value $1.604M Shares 543,753 Est. Cost $9871.60 Unrealized —

— Clovis Oncology, Inc. 0.3%

Value $183K Shares 101,855 Est. Cost $56000.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	498,558	$30.3M	46.4%	$40.26	+46.0%	Common Shares	H17182108
—	Passage Bio, Inc.	4,959,769	$11.71M	17.9%	$17.48	—	Common Stock	702712100
—	Gritstone Oncology, Inc.	3,561,150	$8.618M	13.2%	$7767.86	—	Common Stock	39868T105
—	Adverum Biotechnologies, Inc.	5,068,233	$6.082M	9.3%	$9646.10	—	Common Stock	00773U108
—	Minerva Surgical Inc.	1,673,700	$3.933M	6.0%	$5.14	—	Common Stock	60343F106
—	Aligos Therapeutics, Inc.	2,320,381	$2.808M	4.3%	$27.65	—	Common Stock	01626L105
—	CymaBay Therapeutics, Inc.	543,753	$1.604M	2.5%	$9871.60	—	Common Stock	23257D103
—	Clovis Oncology, Inc.	101,855	$183K	0.3%	$56000.00	—	Common Stock	189464100